Socioeconomic Disparities Associated With MGMT Promoter Methylation Testing for Patients With Glioblastoma
Menée aux Etats-Unis, cette étude analyse les modalités d'utilisation de tests prédictifs basés sur la méthylation du promoteur du gène MGMT pour les patients atteints d'un glioblastome récemment diagnostiqué, et souligne les disparités socioéconomiques dans l'accès à ces tests
Silencing of the DNA-repair MGMT gene via promoter methylation is presently the only clinically relevant predictive biomarker for patients with glioblastoma and, increasingly, a critical eligibility criterion for clinical trial participation. Consequently, National Comprehensive Cancer Network guidelines recommend testing all newly diagnosed glioblastomas. Promoter methylation status of MGMT is particularly important for clinical decision-making for patients who are elderly or frail, who are less able to tolerate multimodal therapy and for whom temozolomide can be withheld due to its limited benefit in MGMT-unmethylated cases. Herein we evaluate the national practice patterns of MGMT testing and identify potential factors associated with access to testing.
JAMA Oncology 2020